These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 17335681)

  • 1. Chelation therapy for iron overload.
    Barton JC
    Curr Gastroenterol Rep; 2007 Mar; 9(1):74-82. PubMed ID: 17335681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
    Neufeld EJ
    Blood; 2006 May; 107(9):3436-41. PubMed ID: 16627763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Iron chelating therapy in adults: How and when ?].
    Ruivard M
    Rev Med Interne; 2013 Jan; 34(1):32-8. PubMed ID: 23195912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron chelation therapy.
    Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Bova C; Filippelli G; Capodanno I; Neri A; Morabito F; Gentile M; Vigna E
    Eur J Haematol; 2023 May; 110(5):490-497. PubMed ID: 36708354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
    Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
    Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of iron overload and chelation with deferasirox.
    Choudhry VP; Naithani R
    Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
    Kolnagou A; Kontoghiorghes GJ
    Front Biosci (Landmark Ed); 2018 Jan; 23(6):1082-1098. PubMed ID: 28930590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M; Borgna-Pignatti C
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
    Voskaridou E; Christoulas D; Terpos E
    Br J Haematol; 2011 Sep; 154(5):654-6. PubMed ID: 21615376
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
    Musallam KM; Barella S; Origa R; Ferrero GB; Lisi R; Pasanisi A; Longo F; Gianesin B; Forni GL;
    Blood Cells Mol Dis; 2024 Jul; 107():102859. PubMed ID: 38820707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
    Forni GL; Kattamis A; Kuo KHM; Maggio A; Sheth S; Taher AT; Viprakasit V
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31035. PubMed ID: 38753107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 18. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron-chelating therapy for transfusional iron overload.
    Brittenham GM
    N Engl J Med; 2011 Jan; 364(2):146-56. PubMed ID: 21226580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How I treat transfusional iron overload.
    Hoffbrand AV; Taher A; Cappellini MD
    Blood; 2012 Nov; 120(18):3657-69. PubMed ID: 22919029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.